Total haircuts, monopolistic companies, expelled from the market!

In fact, in addition to the Prime Minister’s speech, the recently adopted State Council’s institutional reform program has also signaled that anti-monopoly strength and effectiveness will be further strengthened.

The State Council's institutional reform plan puts forward the duties of the State Administration for Industry and Commerce, the responsibility of the General Administration of Quality Supervision, Inspection and Quarantine, and national foods. drug Responsibilities of the General Administration of Supervision, the National Development and Reform Commission’s price supervision and inspection and enforcement of anti-monopoly enforcement duties, the integration of responsibilities of the Ministry of Commerce’s managers to enforce anti-monopoly law enforcement and the State Council’s anti-monopoly committee office, and the establishment of the State Market Supervision and Administration Bureau as a direct under the State Council. mechanism.

The main responsibility of the State Market Supervision Administration is to take charge of the overall supervision and management of the market, to uniformly register market entities and establish information disclosure and sharing mechanisms, to organize comprehensive supervision on market supervision, to assume unified anti-monopoly enforcement, to regulate and maintain market order, and to organize implementation quality. Strong country strategy, responsible for industry product quality Safety, food safety, safety supervision of special equipment, unified management of measurement standards, inspection and inspection, certification and accreditation.

It is not difficult to see that the State Market Supervision Administration, as a directly affiliated institution of the State Council, has integrated the NDRC's duties of price supervision, inspection, and anti-monopoly law enforcement. The Ministry of Commerce's managers have centralized the duties of the anti-monopoly law enforcement and the State Council's anti-monopoly committee office and have assumed responsibility. Uniform enforcement of antitrust laws.

Uniform enforcement by the same organization, compared to the cross-functional functions of the organization, shirking, pushing, etc., enforcement efforts must be greatly enhanced. For this change, the National Committee of the Chinese People's Political Consultative Conference and Chairman of the National Social Security Fund Council Lou Jiwei made an image Metaphor.

"A plough jumped into the water and returned to the Ministry of Agriculture. When you landed on the shore, it was returned to the forestry bureau. ''I planted a peony under the forestry bureau. I changed the planting medicine to the Ministry of Agriculture, because the former is a woody, the latter It is a herb. 'This reform program formed the National Bureau of Forestry and Grassland, 'Forestry and Grassland'.

It can be said that the monopolistic behavior of drug companies later in the water and on the shore cannot escape the unified enforcement of the State Market Supervision Administration.

As for the issue of institutional restructuring, on March 19, the newly elected Deputy Prime Minister of the State Council, Liu Hezeng, wrote in the People's Daily on March 13th that this is a comprehensive reform and that some institutional adjustments will be implemented within a few months.

This means that the anti-monopoly work of the General Administration of Marketing may also be promoted soon.

During the two sessions, many medicine The deputies of the National People's Congress and members of the Chinese People's Political Consultative Conference (CPPCC) stated to the media that the raw material medicines that have long existed in the pharmaceutical field were too concentrated. The unspoken rules such as monopolization have not been solved so far and there has been growing momentum.

Informed sources disclosed to Cypress that the current monopoly of raw material medicine in the domestic pharmaceutical market has become an open secret of the industry, and it has become increasingly fierce. Now that it has developed into a manufacturer, there is no right to speak about the price, and bargaining prices are given by the monopolist.

Wang Xuegong, vice president of the Chinese Pharmaceutical Enterprise Management Association, also told the media that “Last year, the China Pharmaceutical Enterprise Management Association conducted a questionnaire survey on some companies and found that market monopoly control of sales was one of the main causes of the price increase of some raw material medicines.”

Some manufacturers or middlemen raise the price by controlling the supply of all the raw materials of a certain species. Some prices rise several times or several times. The price increase has the highest price within 1-2 years, and the price has risen to 70 times the original price.

Sai Bailan was informed at the National People's Congress deputies and members of the CPPCC National Committee meeting. Such as Hu Jinqiang, chairman of Conba, said that the prices of many raw material medicines have increased by 20-30 times from previous years.

For example, the price of a raw material called uric acid was only 30-40 yuan/kg a few years ago, but in the past two years, the price has risen to 900 yuan/kg once. Finally, the government departments involved in product adjustment to continue production. Hu Jiqiang also 5. It is emphasized that Connehbert’s encounter is by no means a case.

In fact, for some time, monopoly cases of raw material drugs have emerged in an endless stream. For example, three companies in Estazolam, the former Chinese medicine industry, Shandong Xinyi, and Changzhou Four Pharmaceuticals reached a monopoly agreement over the APIs and tablets and were eventually The National Development and Reform Commission penalized the total fine of more than 260 million yuan;

For example, other companies such as Chongqing Qingyang, Chongqing Datong, Jiangsu Shimao Tianjie, Shanghai Xinyi United, and Shangqiu Huajie have implemented a unified price monopoly agreement for APIs. In 2016, the National Development and Reform Commission responded The company penalized the company and fined nearly 4 million yuan in total;

Another example is promethazine hydrochloride. In June 2011, Shandong Weifang Shuntong Pharmaceutical Co., Ltd. and Weifang Huaxin Pharmaceutical Trading Company signed exclusive agreements with two promethazine hydrochloride production companies. proxy Through the control of raw material supply, the agreement monopolized the sales of promethazine hydrochloride in China, raising the sales price from less than 200 yuan per kilogram to between 300 yuan and 1,350 yuan. The two companies were eventually overseen by the National Development and Reform Commission The monopolistic bureau punishes the confiscation of illegal income and a fine of 7 million yuan.

The above is only the tip of the iceberg of a serious monopoly of raw material medicines in China. At present, the monopoly of APIs is concentrated on small varieties. Although these varieties are small, once raw materials are monopolized, they are fatal to the downstream drug companies.

The relevant staff of the National Development and Reform Commission stated that the monopoly of raw material medicines was mainly concentrated in some cities and counties in Shandong, Anhui, Henan, Hubei, Zhejiang and other provinces. Monopolies were more concentrated and often committed crimes.

First of all, the most direct result of monopoly is the price increase. Earlier, Good Doctor Pharmaceutical Chairman Nguyen Fu Neng once said, 'Now, there is a monopoly in the pharmaceutical industry in China, especially in the field of APIs, and some commercial companies will A drug approval number is held in the palm of your hand, allowing drug prices to increase in value by several times or even ten times from the beginning of the raw material.

For example, digoxin tablets, which are of great interest, have publicly disclosed that since September 2014, the price of digoxin tablets has gradually increased from 75,000 yuan per kilogram to 400,000 yuan per kilogram in January 2015.

For another example, in the monopoly case of estazolam, several enterprise After the monopoly agreement was reached, 1mg*20 tablets of estazolam tablets had their raw material prices rise several times since 2015. There were also patient feedbacks. Originally, more than one tablet bought more than one bottle of esmolol. The azole film, rose to 20 yuan by the beginning of 2016.

The rise in prices of APIs has been regarded as a big pusher to push up the price of some drugs. Some downstream pharmaceutical companies have complained that the monopoly of raw material drugs is serious and the pharmaceutical companies can only be allowed to butcher in price.

In addition to price hikes, monopoly will cause certain pharmaceutical companies to stop production or even cause market drug outages due to lack of APIs in some shortages.

This has resulted in significant 'effects' in some cases in the past: After the monopoly of the promethazine hydrochloride drug market, many domestic compound reserpine production enterprises could not afford it and were forced to stop production in July 2011, resulting in an inability to supply. The consequences of tight market supply.

In the estazolam monopoly case, according to the raw material drug sales data retrieved by the National Development and Reform Commission, from 2013 to 2014, three companies supplied APIs to 16 downstream tablet manufacturers, but after October 2014, due to The companies stopped supplying their products to the outside world, causing most tablet manufacturers to stop production due to lack of APIs.

In general, the monopoly of raw material medicines means that pharmaceutical companies have higher and higher levels of dominance in the downstream preparations market. However, downstream pharmaceutical companies have experienced rising costs, and they have to accept thorough exits.

The position of the Prime Minister and the establishment of a new institution are undoubtedly a source of gratification to the downstream pharmaceutical companies that have already been under pressure.